Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations

METNET: A phase II trial of metformin in patients with well differentiated neuroendocrine tumours

EGFR testing: Best practice for NSCLC patients with exon 20 insertions

Survival outcomes of unilateral RB based on pathological risk stratification-experience at a tertiary care centre in Pakistan

SG in combination with pembro in patients with mUC who progressed after platinum (PLT)-based regimens

NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion

Tailoring radiation therapy in the 21st century

Brentuximab vedotin and CHP benefit over CHOP for CD30-positive PTCL

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in aRCC

Pandemic strategising for cancer hospital stockpiles

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022